Dong-A ST Co Ltd

Chart & Performance

D1W1MN

P/E

46.44

P/S

0.78

EPS

1,238.11

Div Yield, %

1.14%

Shrs. gr., 5y

3.41%

Rev. gr., 5y

3.19%

Revenues

663.98b

+4.50%

Net income

11.12b

-17.93%

CFO

3.37b

-89.74%

Dividend

Dec 27, 2023686.27451 KRW/sh

Earnings

Feb 13, 2025

Profile

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen for the treatment of gastritis; Suganon for diabetes treatment; Terizidone for active pulmonary and extra-pulmonary tuberculosis; and Zydena for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high technology medical devices, custom made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

URL

http://www.donga-st.com

IPO date

Apr 08, 2013

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	663,980,368 4.50%	635,392,683 7.11%	593,227,916 1.11%
Cost of revenue	542,465,113	509,149,768	479,051,805
Unusual Expense (Income)
NOPBT	121,515,255	126,242,915	114,176,111
NOPBT Margin	18.30%	19.87%	19.25%
Operating Taxes	3,982,471	4,744,709	(726,570)
Tax Rate	3.28%	3.76%
NOPAT	117,532,784	121,498,206	114,902,681
Net income	11,122,465 -17.93%	13,552,041 5.74%	12,816,149 -52.71%
Dividends	(5,884,218)	(8,440,847)	(8,438,390)
Dividend yield	0.84%	1.39%	1.32%
Proceeds from repurchase of equity	(8,396,534)	(2,146,854)
BB yield	1.19%	0.35%
Debt
Debt current	240,740,683	65,031,934	144,467,077
Long-term debt	172,797,556	250,543,151	162,102,782
Deferred revenue	11,085,691	8,463,041	7,182,211
Other long-term liabilities	54,316,300	15,793,650	9,208,710
Net debt	6,699,902	15,027,137	70,337,394
Cash flow
Cash from operating activities	3,374,042	32,894,833	49,373,804
CAPEX	(27,033,520)	(68,866,567)	(80,440,019)
Cash from investing activities	(109,422,846)	49,412,467	(85,815,865)
Cash from financing activities	54,586,739	(8,898,935)	81,775,851
FCF	84,618,918	98,323,967	65,758,495
Balance
Cash	286,424,998	289,324,561	304,490,445
Long term investments	120,413,340	11,223,387	(68,257,980)
Excess cash	373,639,319	268,778,314	206,571,070
Stockholders' equity	249,699,545	558,863,061	523,002,416
Invested Capital	828,975,049	752,697,843	765,499,207
ROIC	14.86%	16.01%	15.63%
ROCE	10.91%	12.20%	11.61%
EV
Common stock shares outstanding	10,181	10,184	9,275
Price	69,100.00 15.92%	59,607.83 -13.39%	68,819.66 -19.19%
Market cap	703,476,834 15.88%	607,068,613 -4.90%	638,322,167 -14.62%
EV	736,117,855	640,629,979	708,659,560
EBITDA	147,858,305	147,112,835	134,126,400
EV/EBITDA	4.98	4.35	5.28
Interest	12,723,460	8,105,719	5,623,981
Interest/NOPBT	10.47%	6.42%	4.93%